ImmunityBio (IBRX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

IBRX Stock Forecast

ImmunityBio stock forecast is as follows: an average price target of $8.00 (represents a 205.34% upside from IBRX’s last price of $2.62) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

IBRX Price Target

The average price target for ImmunityBio (IBRX) is $8.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 205.34% upside from IBRX's last price of $2.62.

IBRX Analyst Ratings

Buy

According to 2 Wall Street analysts, ImmunityBio's rating consensus is 'Buy'. The analyst rating breakdown for IBRX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).

ImmunityBio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 03, 2022	Kelly Shi	Jefferies	$8.00	$4.13	93.94%	205.34%

The latest ImmunityBio stock forecast, released on Aug 03, 2022 by Kelly Shi from Jefferies, set a price target of $8.00, which represents a 93.94% increase from the stock price at the time of the forecast ($4.13), and a 205.34% increase from IBRX last price ($2.62).

ImmunityBio Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$2.62	$2.62	$2.62
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of ImmunityBio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ImmunityBio's last price of $2.62. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 23, 2024	EF Hutton		Buy	Initialise
Apr 26, 2022	Zacks Investment Research		Sell	Downgrade

ImmunityBio's last stock rating was published by EF Hutton on Oct 23, 2024. The company Initialise its IBRX rating from "null" to "Buy".

ImmunityBio Financial Forecast

ImmunityBio Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$139.00K	$360.00K	$73.00K	$118.00K	$35.00K	$14.00K	$390.00K	$66.00K	$339.00K	$139.00K
Avg Forecast	$973.40M	$935.97M	$935.97M	$898.53M	$387.24M	$372.35M	$372.35M	$357.46M	$122.94M	$118.22M	$118.22M	$113.49M	$43.45M	$40.10M	$36.35M	$30.49M	$5.85M	$2.92M	$14.71M	$62.50K	$25.00K	$25.00K	$25.00K	$118.00K	$25.00K	$25.00K	$25.00K	$25.00K	$25.00K	$25.00K
High Forecast	$973.40M	$935.97M	$935.97M	$898.53M	$387.24M	$372.35M	$372.35M	$357.46M	$122.94M	$118.22M	$118.22M	$113.49M	$43.45M	$40.10M	$36.35M	$30.49M	$6.07M	$2.92M	$14.71M	$62.50K	$25.00K	$25.00K	$25.00K	$118.00K	$25.00K	$25.00K	$25.00K	$25.00K	$25.00K	$25.00K
Low Forecast	$973.40M	$935.97M	$935.97M	$898.53M	$387.24M	$372.35M	$372.35M	$357.46M	$122.94M	$118.22M	$118.22M	$113.49M	$43.45M	$40.10M	$36.35M	$30.49M	$5.62M	$2.92M	$14.71M	$62.50K	$25.00K	$25.00K	$25.00K	$118.00K	$25.00K	$25.00K	$25.00K	$25.00K	$25.00K	$25.00K
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.56%	14.40%	2.92%	1.00%	1.40%	0.56%	15.60%	2.64%	13.56%	5.56%

ImmunityBio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $62.50K, with a low forecast of $62.50K, and a high forecast of $62.50K. IBRX's average Quarter revenue forecast represents a -55.04% decrease compared to the company's last Quarter revenue of $139.00K (Dec 23).

ImmunityBio EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-79.94M	$-109.79M	$-82.93M	$-90.51M	$-78.70M	$-91.84M	$-83.17M	$-80.33M	$-80.72M	$-73.47M
Avg Forecast	$-973.40M	$-935.97M	$-935.97M	$-898.53M	$-387.24M	$-372.35M	$-372.35M	$-357.46M	$-122.94M	$-118.22M	$-118.22M	$-113.49M	$-43.45M	$-40.10M	$-36.35M	$-30.49M	$-5.85M	$-2.92M	$-14.71M	$-62.50K	$-25.00K	$-25.00K	$-25.00K	$-118.00K	$-25.00K	$-73.84M	$-25.00K	$-25.00K	$-25.00K	$-98.38M
High Forecast	$-973.40M	$-935.97M	$-935.97M	$-898.53M	$-387.24M	$-372.35M	$-372.35M	$-357.46M	$-122.94M	$-118.22M	$-118.22M	$-113.49M	$-43.45M	$-40.10M	$-36.35M	$-30.49M	$-5.62M	$-2.92M	$-14.71M	$-62.50K	$-25.00K	$-25.00K	$-25.00K	$-118.00K	$-25.00K	$-59.07M	$-25.00K	$-25.00K	$-25.00K	$-78.70M
Low Forecast	$-973.40M	$-935.97M	$-935.97M	$-898.53M	$-387.24M	$-372.35M	$-372.35M	$-357.46M	$-122.94M	$-118.22M	$-118.22M	$-113.49M	$-43.45M	$-40.10M	$-36.35M	$-30.49M	$-6.07M	$-2.92M	$-14.71M	$-62.50K	$-25.00K	$-25.00K	$-25.00K	$-118.00K	$-25.00K	$-88.60M	$-25.00K	$-25.00K	$-25.00K	$-118.05M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3197.56%	4391.56%	3317.12%	767.04%	3148.12%	1.24%	3326.92%	3213.12%	3229.00%	0.75%

undefined analysts predict IBRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ImmunityBio's previous annual EBITDA (undefined) of $NaN.

ImmunityBio Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-233.39M	$-151.16M	$-108.33M	$-110.94M	$-94.59M	$-102.83M	$-91.55M	$-87.63M	$-89.39M	$-80.48M
Avg Forecast	$417.38M	$405.72M	$410.26M	$372.43M	$125.07M	$123.96M	$128.63M	$118.44M	$-31.97M	$-25.75M	$-19.68M	$-25.68M	$-86.37M	$-85.78M	$-86.20M	$-92.31M	$-156.34M	$-124.26M	$-111.67M	$-136.10M	$-125.63M	$-188.45M	$-153.55M	$-192.34M	$-164.87M	$-84.13M	$-144.26M	$-137.39M	$-82.43M	$-106.61M
High Forecast	$417.38M	$405.72M	$410.26M	$372.43M	$125.07M	$123.96M	$128.63M	$118.44M	$-31.97M	$-25.75M	$-19.68M	$-25.68M	$-86.37M	$-85.78M	$-86.20M	$-92.31M	$-102.22M	$-124.26M	$-111.67M	$-136.10M	$-125.63M	$-188.45M	$-153.55M	$-192.34M	$-164.87M	$-67.30M	$-144.26M	$-137.39M	$-82.43M	$-85.28M
Low Forecast	$417.38M	$405.72M	$410.26M	$372.43M	$125.07M	$123.96M	$128.63M	$118.44M	$-31.97M	$-25.75M	$-19.68M	$-25.68M	$-86.37M	$-85.78M	$-86.20M	$-92.31M	$-204.45M	$-124.26M	$-111.67M	$-136.10M	$-125.63M	$-188.45M	$-153.55M	$-192.34M	$-164.87M	$-100.96M	$-144.26M	$-137.39M	$-82.43M	$-127.93M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.86%	0.80%	0.71%	0.58%	0.57%	1.22%	0.63%	0.64%	1.08%	0.75%

ImmunityBio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IBRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

ImmunityBio SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$29.05M	$32.68M	$26.21M	$19.31M	$16.57M	$40.61M	$27.91M	$29.63M	$32.45M	$45.27M
Avg Forecast	$179.13B	$172.24B	$172.24B	$165.35B	$71.26B	$68.52B	$68.52B	$65.78B	$22.62B	$21.75B	$21.75B	$20.88B	$8.00B	$7.38B	$6.69B	$5.61B	$1.08B	$538.28M	$2.71B	$11.50M	$4.60M	$4.60M	$4.60M	$21.72M	$4.60M	$4.60M	$4.60M	$4.60M	$4.60M	$4.60M
High Forecast	$179.13B	$172.24B	$172.24B	$165.35B	$71.26B	$68.52B	$68.52B	$65.78B	$22.62B	$21.75B	$21.75B	$20.88B	$8.00B	$7.38B	$6.69B	$5.61B	$1.12B	$538.28M	$2.71B	$11.50M	$4.60M	$4.60M	$4.60M	$21.72M	$4.60M	$4.60M	$4.60M	$4.60M	$4.60M	$4.60M
Low Forecast	$179.13B	$172.24B	$172.24B	$165.35B	$71.26B	$68.52B	$68.52B	$65.78B	$22.62B	$21.75B	$21.75B	$20.88B	$8.00B	$7.38B	$6.69B	$5.61B	$1.03B	$538.28M	$2.71B	$11.50M	$4.60M	$4.60M	$4.60M	$21.72M	$4.60M	$4.60M	$4.60M	$4.60M	$4.60M	$4.60M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.31%	7.10%	5.70%	0.89%	3.60%	8.83%	6.07%	6.44%	7.05%	9.84%

ImmunityBio's average Quarter SG&A projection for Mar 24 is $11.50M, based on 1 Wall Street analysts, with a range of $11.50M to $11.50M. The forecast indicates a -60.40% fall compared to IBRX last annual SG&A of $29.05M (Dec 23).

ImmunityBio EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.35	$-0.35	$-0.27	$-0.28	$-0.24	$-0.26	$-0.23	$-0.22	$-0.23	$-0.21
Avg Forecast	$0.60	$0.58	$0.59	$0.53	$0.18	$0.18	$0.18	$0.17	$-0.05	$-0.04	$-0.03	$-0.04	$-0.12	$-0.12	$-0.12	$-0.13	$-0.22	$-0.18	$-0.16	$-0.20	$-0.18	$-0.27	$-0.22	$-0.28	$-0.24	$-0.22	$-0.21	$-0.20	$-0.12	$-0.41
High Forecast	$0.60	$0.58	$0.59	$0.53	$0.18	$0.18	$0.18	$0.17	$-0.05	$-0.04	$-0.03	$-0.04	$-0.12	$-0.12	$-0.12	$-0.13	$-0.15	$-0.18	$-0.16	$-0.20	$-0.18	$-0.27	$-0.22	$-0.28	$-0.24	$-0.22	$-0.21	$-0.20	$-0.12	$-0.41
Low Forecast	$0.60	$0.58	$0.59	$0.53	$0.18	$0.18	$0.18	$0.17	$-0.05	$-0.04	$-0.03	$-0.04	$-0.12	$-0.12	$-0.12	$-0.13	$-0.29	$-0.18	$-0.16	$-0.20	$-0.18	$-0.27	$-0.22	$-0.28	$-0.24	$-0.22	$-0.21	$-0.20	$-0.12	$-0.41
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.94%	1.30%	1.23%	1.00%	1.00%	1.18%	1.10%	1.10%	1.92%	0.51%

According to undefined Wall Street analysts, ImmunityBio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IBRX previous annual EPS of $NaN (undefined).

ImmunityBio Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ELEV	Elevation Oncology	$0.67	$9.00	1243.28%	Buy
CVAC	CureVac	$2.95	$29.00	883.05%	Buy
LXRX	Lexicon Pharmaceuticals	$0.73	$6.00	721.92%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
PDSB	PDS Bio	$1.96	$9.00	359.18%	Buy
VIR	Vir Bio	$7.35	$28.00	280.95%	Buy
IBRX	ImmunityBio	$2.83	$8.00	182.69%	Buy
ARDX	Ardelyx	$4.66	$11.00	136.05%	Buy
VKTX	Viking Therapeutics	$46.70	$97.80	109.42%	Buy
MCRB	Seres Therapeutics	$0.88	$1.25	42.05%	Buy
KRYS	Krystal Biotech	$169.04	$210.33	24.43%	Buy
MDGL	Madrigal Pharmaceuticals	$306.08	$315.75	3.16%	Buy
TGTX	TG Therapeutics	$33.57	$23.75	-29.25%	Buy

IBRX Forecast FAQ

Is ImmunityBio a good buy?

Yes, according to 2 Wall Street analysts, ImmunityBio (IBRX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of IBRX's total ratings.

What is IBRX's price target?

ImmunityBio (IBRX) average price target is $8 with a range of $8 to $8, implying a 205.34% from its last price of $2.62. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will ImmunityBio stock go up soon?

According to Wall Street analysts' prediction for IBRX stock, the company can go up by 205.34% (from the last price of $2.62 to the average price target of $8), up by 205.34% based on the highest stock price target, and up by 205.34% based on the lowest stock price target.

Can ImmunityBio stock reach $4?

IBRX's average twelve months analyst stock price target of $8 supports the claim that ImmunityBio can reach $4 in the near future.

What are ImmunityBio's analysts' financial forecasts?

ImmunityBio's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $1.49B (high $1.49B, low $1.49B), average EBITDA is $-1.489B (high $-1.489B, low $-1.489B), average net income is $496.11M (high $496.11M, low $496.11M), average SG&A $274.09B (high $274.09B, low $274.09B), and average EPS is $0.711 (high $0.711, low $0.711). IBRX's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $3.74B (high $3.74B, low $3.74B), average EBITDA is $-3.744B (high $-3.744B, low $-3.744B), average net income is $1.61B (high $1.61B, low $1.61B), average SG&A $688.97B (high $688.97B, low $688.97B), and average EPS is $2.3 (high $2.3, low $2.3).

Did the IBRX's actual financial results beat the analysts' financial forecasts?

Based on ImmunityBio's last annual report (Dec 2023), the company's revenue was $622K, beating the average analysts forecast of $50K by 1144.00%. Apple's EBITDA was $-343M, beating the average prediction of $-50K by 685604.00%. The company's net income was $-583M, beating the average estimation of $-314M by 85.68%. Apple's SG&A was $129.62M, beating the average forecast of $9.2M by 1308.71%. Lastly, the company's EPS was $-1.15, beating the average prediction of $-0.45 by 155.56%. In terms of the last quarterly report (Dec 2023), ImmunityBio's revenue was $139K, beating the average analysts' forecast of $25K by 456.00%. The company's EBITDA was $-79.939M, beating the average prediction of $-25K by 319656.00%. ImmunityBio's net income was $-233M, beating the average estimation of $-126M by 85.77%. The company's SG&A was $29.05M, beating the average forecast of $4.6M by 531.34%. Lastly, the company's EPS was $-0.35, beating the average prediction of $-0.18 by 94.44%